1. An increase in which of the following is a main contributor to the disordered iron homeostasis and anemia of CKD by impairing dietary iron absorption and iron mobilization from body stores?

2. Which of the following is true regarding the mechanism of action of HIF-PH inhibition?

3. Based on pooled results from phase 3 clinical trials in patients with ND-CKD and anemia, what effects were observed on iron indices with roxadustat versus placebo, respectively, relative to baseline values?

4. Based on pooled results from phase 3 clinical trials of HIF-PH inhibitors in patients with DD-CKD and anemia, treatment with which of the following would likely reduce the risk of death, myocardial infarction, stroke, heart failure, and unstable angina requiring hospitalization?

5. You are the pharmacy director of a CKD clinic participating in the Advancing American Kidney Health initiative. One of the patients in your clinic is a 67-year-old man with longstanding hypertension, diabetic nephropathy, 3-year history of hemodialysis, and recent labs that include Hb = 9.5 g/dL, TSAT = 19%, and ferritin = 900 mcg/L who is being treated with 50 mg/mo IV iron sucrose. He is not tolerating iron therapy well and has been nonresponsive to increased doses of darbepoetin alfa. The nursing supervisor suggests enrolling him in a HIF-PH inhibitor clinical trial and states that a HIF-PH inhibitor should improve his anemia and reduce the need for IV iron. What would you say in reply?

« Return to Activity